RetinalGenix Technologies Inc. (RTGN)
USD 53.0
(88.0%)
USD 53.0
(88.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.08 Million USD | -11.25% |
| 2022 | -1.87 Million USD | -25.36% |
| 2021 | - USD | 9.11% |
| 2020 | - USD | -104.32% |
| 2019 | - USD | -55093.15% |
| 2018 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.14 Million USD | -296.72% |
| 2024 Q2 | -662.64 Thousand USD | 69.11% |
| 2023 FY | - USD | -11.25% |
| 2023 Q4 | -540.66 Thousand USD | 21.13% |
| 2023 Q2 | -351.15 Thousand USD | 31.1% |
| 2023 Q1 | -509.65 Thousand USD | 56.27% |
| 2023 Q3 | -685.48 Thousand USD | -95.21% |
| 2022 Q1 | -216.24 Thousand USD | 47.04% |
| 2022 Q4 | -1.16 Million USD | -328.72% |
| 2022 Q3 | -271.83 Thousand USD | -22.21% |
| 2022 FY | - USD | -25.36% |
| 2022 Q2 | -222.43 Thousand USD | -2.86% |
| 2021 Q1 | -683.68 Thousand USD | -69.3% |
| 2021 FY | - USD | 9.11% |
| 2021 Q4 | -408.3 Thousand USD | 25.74% |
| 2021 Q3 | -549.84 Thousand USD | 19.58% |
| 2021 Q2 | -683.68 Thousand USD | 0.0% |
| 2020 Q2 | -1.00 USD | 0.0% |
| 2020 Q4 | -403.83 Thousand USD | 13.75% |
| 2020 FY | - USD | -104.32% |
| 2020 Q3 | -468.2 Thousand USD | -46820100.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | - USD | -55093.15% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | 84.526% |
| Biotricity, Inc. | -8.82 Million USD | 76.361% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -113.825% |
| Nemaura Medical Inc. | -7.28 Million USD | 71.361% |
| PetVivo Holdings, Inc. | -10.49 Million USD | 80.114% |
| Sonendo, Inc. | -54.76 Million USD | 96.189% |
| Telesis Bio, Inc. | -40.49 Million USD | 94.846% |
| Talis Biomedical Corporation | -66.04 Million USD | 96.84% |
| Viveve Medical, Inc. | -20.61 Million USD | 89.878% |